Abstract
BackgroundAdalimumab is a subcutaneous anti-tumour necrosis factor antibody therapy used in the treatment of numerous pathologies related to rheumatology, dermatology and gastroenterology. This drug is on the top ranking of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
